Browse the evidence

Longer-muscle length resistance training (LML-RT) produces greater muscle hypertrophy than shorter-muscle length resistance training (SML-RT).

To maximize muscle growth, prioritize exercises that allow you to train at longer muscle lengths (e.g., deep squats, overhead presses, or lengthened partials). While you can still grow with partial ROM, the evidence suggests that loading the muscle in its stretched position yields superior hypertrophy, particularly in the distal regions of the muscle.

Carbohydrate-modified diets (low glycemic load, high fiber, or reduced-CHO) are more effective for weight loss or weight regain prevention in individuals with impaired glucose metabolism (prediabetes, IFG, or IGT) compared to those with normal glucose tolerance, supporting the hypothesis of precision nutrition based on glycemic status.

If you have prediabetes or impaired glucose tolerance, you may lose more weight or prevent weight regain by choosing a carbohydrate-modified diet (such as low glycemic load, high fiber, or reduced carbohydrate) compared to a standard high-carbohydrate diet. While the evidence is not yet definitive, this approach aligns with your body's likely insulin resistance. Consult a healthcare provider for testing and personalized guidance.

Women with type 2 diabetes treated with GLP-1 receptor agonists achieve significantly greater weight loss than men after 12 months, despite similar glycemic control improvements.

If you are a woman with Type 2 Diabetes on a GLP-1 agonist, you are statistically more likely to achieve significant weight loss (over 5% or 10%) than a man on the same medication class, particularly after 6-12 months. This does not mean men won't lose weight, but the magnitude of benefit tends to be greater in women. Glycemic control (HbA1c) improves similarly for both sexes.

Obesity significantly impairs work productivity and daily activities, with over 25% of work time impaired due to obesity status, and this impairment is greater in patients with obesity-related complications.

If you feel like obesity is affecting your work or daily activities, it is likely having a measurable impact. This impairment is a recognized part of the disease burden. Effective treatment of obesity may help reduce this impairment and improve your quality of life and productivity.

Glucagon receptor (GCGR) agonism increases energy expenditure and promotes weight loss, particularly when combined with GLP-1R and/or GIPR agonism in dual or triple receptor agonists.

Current obesity treatments often lead to weight regain because they don't significantly increase energy expenditure. New drugs that activate the glucagon receptor (GCGR), either alone or combined with GLP-1/GIP drugs, are designed to boost energy expenditure and prevent this metabolic slowdown. While early results show significant weight loss (up to 24% in some trials), long-term clinical data is still emerging, and these are prescription medications requiring medical supervision.

In a mixed population of diabetic and non-diabetic patients, liraglutide (up to 3 mg) and semaglutide (up to 1 mg) produce statistically equivalent weight loss, contradicting findings from trials using higher doses or specific diabetic cohorts.

If you are using liraglutide or semaglutide at lower, standard starting-to-maintenance doses (up to 3mg and 1mg respectively), expect similar weight loss results. The perceived superiority of semaglutide in marketing often relies on higher doses (2.4mg) not used in this study. Focus on adherence and titration rather than switching solely for weight loss efficacy at these doses.

Concomitant use of SGLT2 inhibitors significantly enhances weight loss in patients taking GLP-1 receptor agonists, independent of the specific GLP-1 RA used.

If weight loss stalls on a GLP-1 RA, discuss adding an SGLT2 inhibitor. This study found that using both together significantly improved weight loss outcomes compared to using GLP-1 RAs alone, likely due to complementary mechanisms.

Higher baseline BMI and the presence of symptomatic comorbidities (specifically knee osteoarthritis or obstructive sleep apnoea) are associated with greater improvements in health utility scores following semaglutide 2.4 mg treatment.

If you have a higher BMI (over 35 or 40) and suffer from knee osteoarthritis or sleep apnea, semaglutide 2.4 mg once weekly may offer even greater improvements in your daily health quality of life than it would for someone with a lower BMI or fewer comorbidities.

Digital weight-loss services utilizing GLP-1 receptor agonists exhibit a prescribing error rate of 4.4%, with the most prevalent errors being insufficient safety counseling (49.15%) and inadequate investigation of contraindications (30.29%).

If you are using a digital service for GLP-1 RAs, expect a thorough intake process. The most common errors are not about the drug dose, but about skipping safety checks. Ensure you answer all health questions accurately, especially regarding family history and other medications, as this protects you from serious side effects. The 4.4% error rate in this large study is relatively low, indicating that digital services can be safe when they enforce multidisciplinary oversight.

Tirzepatide-supported digital weight loss programs achieve high mean weight loss (13.8% over 16 weeks) and high engagement rates, but proactive coaching messaging does not significantly improve weight loss outcomes compared to reactive or control models.

Tirzepatide delivers substantial weight loss (approx 14% in 16 weeks) even with minimal coaching interaction. You do not need to send frequent messages to your coach to lose weight; the medication is the primary driver. Focus on adherence to the dosing schedule and monitoring for side effects rather than trying to maximize engagement metrics.

Bodybuilders who consume dietary supplements (DS) frequently experience adverse side effects, specifically skin rashes (21%), increased liver enzymes (10.8%), and hair loss (9.4%).

If you are taking dietary supplements, monitor your body for changes. The most common issues reported by bodybuilders are skin rashes, hair loss, and elevated liver enzymes. If you notice these symptoms, consult a healthcare provider and review your supplement stack, as they may be contaminated or causing physiological stress.

In middle-aged and older adults, weight gain is associated with an increased risk of atherosclerosis (measured by cIMT > 1.0 mm), particularly in those under 65, those with prior cardiovascular events, and those who are overweight or obese at baseline.

For adults over 45, gaining weight is a clear risk factor for developing atherosclerosis, especially if you are already overweight, obese, or have had heart issues. Focus on maintaining a stable, healthy weight rather than chasing rapid weight loss, which may not improve arterial health markers in this age group.

Digital dietary interventions specifically lead to greater reductions in body weight, BMI, and fasting blood glucose compared to nondigital dietary interventions.

If you are focusing on diet, using a digital tool (app, wearable) may yield better results for weight loss and blood sugar control than traditional methods like pamphlets or face-to-face counseling alone.

Digital physical activity interventions specifically lead to greater reductions in total cholesterol compared to nondigital physical activity interventions.

If you are focusing on exercise, using a digital tool (app, wearable) may yield better results for cholesterol control than traditional exercise programs alone.

Combined digital interventions (dietary, physical activity, and smoking cessation) significantly decrease BMI compared to nondigital combined interventions.

If you are making multiple lifestyle changes (diet, exercise, quitting smoking), using a digital tool may yield better results for BMI reduction than traditional methods alone.

In healthy adults, belonging to the second quartile of dietary glycemic index (GI) is associated with significantly lower odds of having elevated fasting blood glucose (hyperglycemia) compared to the lowest quartile.

You don't need to aim for the absolute lowest glycemic index foods to maintain healthy blood sugar. A moderate GI (second quartile) was associated with lower odds of high fasting blood glucose in this study. Focus on a balanced diet rather than extreme low-GI restrictions.

Replacing servings of low-quality carbohydrates or animal protein with high-quality carbohydrates or plant protein reduces phenotypic age acceleration (PhenoAgeAccel).

To slow biological aging, focus on swapping food sources rather than just cutting calories. Replace one serving of refined grains, sugary drinks, or animal meat with one serving of whole grains, vegetables, nuts, soy, or plant proteins. This substitution is associated with a significant reduction in biological age markers.

High-quality carbohydrate intake is associated with reduced phenotypic age acceleration, but the relationship is non-linear, with potential adverse effects at excessive intake levels.

While high-quality carbohydrates (whole grains, vegetables) generally slow aging, the benefit is not linear. Very high intake may not provide additional benefits and could be detrimental. Aim for a balanced intake of these foods as part of a substitution strategy rather than maximizing them.

BMI mediates the association between macronutrient quality and phenotypic age acceleration, accounting for approximately 20-30% of the effect.

Dietary changes slow aging partly by helping you maintain a healthy weight. If you are trying to slow biological aging, combining high-quality food choices with weight management strategies will be more effective than diet alone.

Shortened sleep duration (40% reduction for 4 nights) impairs adrenergic stimulation of lipolysis in postmenopausal women, reducing lipid efflux and potentially promoting abdominal adiposity independent of caloric intake.

If you are a postmenopausal woman struggling with abdominal fat despite diet and exercise, check your sleep. This research shows that even short-term sleep restriction (reducing sleep by 40% for just 4 nights) blunts your body's ability to break down fat (lipolysis). Prioritizing adequate sleep duration is a critical, often overlooked lever for managing abdominal adiposity in this demographic.

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

Semaglutide and tirzepatide reduce 'food noise' (constant, pervasive thoughts about food), thereby lowering the mental burden and executive load required to maintain dietary behavior change.

If you feel constantly distracted by thoughts of food ('food noise') despite trying to diet, this is a recognized barrier, not just a lack of willpower. Medications like semaglutide and tirzepatide may reduce this mental burden, making it easier to make deliberate food choices without constant compulsive thinking. This mental relief is often reported as improving quality of life independently of the scale weight.

Semaglutide and tirzepatide increase self-trust and executive functioning regarding food choices by reducing physiological hunger and emotional compulsion, allowing for more deliberate dietary decisions.

If you know what to eat but struggle to follow through due to hunger, cravings, or emotional eating, these medications may help by reducing the physiological drive and emotional compulsion. This can restore your ability to trust yourself and make deliberate, planned food choices rather than reactive ones.

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.